1. Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. The scope of the Study
2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.3. Analytics Tools & Model
2.4. Economic Indicators
2.4.1.Base Year, Base Currency & Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
3. Market Analysis
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1 Bargaining Power of Suppliers
3.2.2 Bargaining Power of Buyers
3.2.3 Threat of Substitutes
3.2.4 Threat of New Entrants
3.2.5 Industry Rivalry (Competitive Environment)
3.3. PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4. SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.4.5 Y-O-Y Analysis
4. Market Dynamics
4.1. Drivers
4.1.1 Rise in cancer incidences and modern therapeutics.
4.1.2 Inclination in Aging population.
4.1.3 Efficiency and high price magnetise manufacturers.
4.1.4. Innovations and improvements to promote the market growth.
4.2. Restraints
4.2.1 High price therapies.
4.2.2 Changes in reimbursement processes.
4.3. Opportunities
4.3.1. Awareness regarding molecular diagnostics techniques.
4.3.2. Insurance coverage, aids in revenue growth of cancer therapies.
4.4. Challenges
4.4.1 Challenges encountered in clinical trials are retraining cancer therapy market.
5. The Middle East and Africa Cancer Therapies Market – By Treatment Type
5.1 Introduction
5.2 Surgery
5.3 Chemotherapy
5.4 Radiation Therapy
5.5 Targeted Therapy
5.6 Immunotherapy (Biologic Therapy)
5.7 Hormonal Therapy
5.8 Hyperthermia
5.9 Stem Cell Transplant
5.10 Signal Transduction Inhibitors
5.11 Gene Expression Modulators
5.12 Apoptosis Inducers
5.13 Angiogenesis Inhibitors
5.14 Others
6. The Middle East and Africa Cancer Therapies Market – By Cancer Type
6.1 Introduction
6.2 Blood Cancer
6.3 Bone Cancer
6.4 Brain Cancer
6.5 Breast Cancer
6.6 Digestive/ Gastrointestinal Cancer
6.7 Endocrine Cancer
6.8 Eye Cancer
6.9 Genitourinary Cancer
6.10 Gynecologic Cancer
6.11 Head & Neck Cancers
6.12 Respiratory/Lung Cancer
6.13 Skin Cancer
7. Middle East and Africa Cancer Therapies Market – By Targeted cancer therapeutics
7.1 Introduction
7.2 Targeted Cancer Therapeutics
7.3 Hormone Therapies
7.4 Signal Transduction Inhibitors
7.5 Gene Expression Modulators
7.6 Apoptosis Inducers
7.7 Angiogenesis Inhibitors
7.8 Immunotherapies
7.8.1 Monoclonal Antibodies
7.8.1.1 Naked Monoclonal Antibodies
7.8.1.2 Conjugated Monoclonal Antibodies
7.8.1.2.1 Radiolabeled Antibodies
7.8.1.2.2 Chemolabeled Antibodies
7.9 Cancer Vaccines
7.9.1 Vaccines to Help Prevent Cancer
7.9.2 Vaccines to Help Treat Cancer
7.10 Non-Specific Immunotherapies
7.10.1 Interferons
7.10.2 Interleukins.
8. Middle East and Africa Cancer Therapies Market – By Application
8.1 Introduction
8.2 Nasal Spray
8.3 Pills or Tablets, Taken By Mouth
8.4 Skin Gel
8.5 Skin Patches
8.6 Vaginal Creams or Vaginal Tablets
8.7 Vaginal Ring
9. The Middle East and Africa Cancer Therapies Market – By Technology
9.1 Introduction
9.2 Types of Agents
9.2.1 Alkylating Agents
9.2.2 Anti-Metabolites
9.2.3 Anti-Microtubule Agents
9.2.4 Topoisomerase Inhibitors
9.2.5 Cytotoxic Antibiotics
9.3 Chemotherapy Regimens
9.3.1 Breast Cancer
9.3.2 Hodgkin's Disease
9.3.3 Germ Cell Tumor
9.3.4 Stomach Cancer
9.3.5 Bladder Cancer
9.3.6 Lung Cancer
10. The Middle East and Africa Cancer Therapies Market – By Geography
10.1 Introduction
10.2 The Middle East and Africa
10.2.1 Introduction
10.2.2 Middle East
10.2.3 Africa
11. The Middle East and Africa Cancer Therapies Market - Company Profiles
11.1 Novartis
11.2 AstraZeneca Plc
11.3 Genentech Inc.
11.4 Chugai pharmaceutical co Ltd
11.5 GlaxoSmithKline plc
11.6 GPC Biotech Ag
11.7 Bayer
11.8 Pfizer
11.9 Sanofi
11.10 Osi pharmaceutical
11.11 Abbott laboratories
11.12 Aveo pharmaceuticals
11.13 Hospira Inc.,
11.14 Boehringer Ingelheim GmbH
12. The Middle East and Africa Cancer Therapies Market - Competitive Landscape
12.1 Market Share Analysis
12.2 Strategies Adopted by top companies
12.3 Merges, Acquisitions, Collaborations & Agreements
13. Market Insights
13.1 Industry Experts Insights
13.2 Analysts Opinions
13.3 Investment Opportunities
14. Appendix
14.1 List of tables
14.2 List of figures
